| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| rgb-286638 | cyclin-dependent kinase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.27 | phase 1 | inhibitor |
| rgb-286638 | cyclin-dependent kinase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.27 | phase 1 | unknown |
| rgb-286638 | cyclin-dependent kinase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.21 | phase 1 | unknown |
| rgb-286638 | cyclin-dependent kinase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.21 | phase 1 | inhibitor |
| rgb-286638 | cyclin-dependent kinase 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
3.26 | phase 1 | inhibitor |
| rgb-286638 | cyclin-dependent kinase 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
3.26 | phase 1 | unknown |
| rgb-286638 | cyclin-dependent kinase 4 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.47 | phase 1 | unknown |
| rgb-286638 | cyclin-dependent kinase 4 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.47 | phase 1 | inhibitor |
| rgb-286638 | cyclin-dependent kinase 9 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.56 | phase 1 | inhibitor |
| rgb-286638 | cyclin-dependent kinase 9 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Hematologic Neoplasms[MeSHID:D019337] |
0.56 | phase 1 | unknown |
| click here to return to the previous page | ||||||||